<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>trsgo dergisi</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Türk Jinekolojik Onkoloji Dergisi</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">2148-5372</issn>
                                        <issn pub-type="epub">2980-1443</issn>
                                                                                            <publisher>
                    <publisher-name>Türk Jinekolojik Onkoloji Derneği</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Gynecologic Oncology Surgery</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Jinekolojik Onkoloji Cerrahisi</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="tr">
                                    <trans-title>HPV 16/18 Pozitif Kadınlarda CIN3 Tanısında Sistemik Enflamatuvar Belirteçlerin Yeri: Retrospektif Bir Çalışma</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>The Association Between Systemic Inflammatory Markers and CIN3+ in Women Positive for HPV 16/18: A Retrospective Study</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-5560-2162</contrib-id>
                                                                <name>
                                    <surname>Özdemir</surname>
                                    <given-names>Cem Yağmur</given-names>
                                </name>
                                                                    <aff>AFYONKARAHİSAR DEVLET HASTANESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Çiçekli</surname>
                                    <given-names>Nayif</given-names>
                                </name>
                                                                    <aff>Erzurum Şehir Hastanesi</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-5224-7679</contrib-id>
                                                                <name>
                                    <surname>Gürer</surname>
                                    <given-names>Ahmet Orhan</given-names>
                                </name>
                                                                    <aff>Afyonkarahisar Devlet Hastanesi</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0009-0003-9290-1534</contrib-id>
                                                                <name>
                                    <surname>Özdemir</surname>
                                    <given-names>Nagihan</given-names>
                                </name>
                                                                    <aff>Afyonkarahisar Sağlık Bilimleri Üniversitesi</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-5762-6723</contrib-id>
                                                                <name>
                                    <surname>Canseven</surname>
                                    <given-names>Elif</given-names>
                                </name>
                                                                    <aff>SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, BURSA YÜKSEK İHTİSAS SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0009-0008-6153-4213</contrib-id>
                                                                <name>
                                    <surname>Doğu</surname>
                                    <given-names>Cevdet</given-names>
                                </name>
                                                                    <aff>Afyonkarahisar Devlet Hastanesi</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0003-3616-0789</contrib-id>
                                                                <name>
                                    <surname>Arıöz</surname>
                                    <given-names>Dağıstan Tolga</given-names>
                                </name>
                                                                    <aff>Afyonkarahisar Sağlık Bilimleri Üniversitesi</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20260422">
                    <day>04</day>
                    <month>22</month>
                    <year>2026</year>
                </pub-date>
                                        <volume>26</volume>
                                        <issue>1</issue>
                                        <fpage>1</fpage>
                                        <lpage>8</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20260226">
                        <day>02</day>
                        <month>26</month>
                        <year>2026</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20260418">
                        <day>04</day>
                        <month>18</month>
                        <year>2026</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2014, Türk Jinekolojik Onkoloji Dergisi</copyright-statement>
                    <copyright-year>2014</copyright-year>
                    <copyright-holder>Türk Jinekolojik Onkoloji Dergisi</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="tr">
                            <p>ÖZET Amaç: Bu çalışmada, HPV 16 ve/veya 18 pozitif kadınlarda sistemik immün-inflamasyon indeksinin (SII) CIN3+ lezyonları bağımsız olarak öngörüp öngöremeyeceğinin değerlendirilmesi amaçlandı. Gereç ve Yöntem: Retrospektif olarak tasarlanan bu çalışmaya, kolposkopik biyopsi yapılan ve HPV 16 ve/veya 18 pozitifliği saptanan 203 kadın dahil edildi. Biyopsi öncesi tam kan sayımı parametrelerinden nötrofil-lenfosit oranı, trombosit-lenfosit oranı ve sistemik immün-inflamasyon indeksi hesaplandı. CIN3+ öngörüsünde SII’nin performansı için ROC eğrisi analizi yapıldı ve optimal eşik değer Youden indeksi ile belirlendi. Bağımsız ilişkiyi değerlendirmek amacıyla çok değişkenli lojistik regresyon analizi uygulandı. Sonuçlar: Hastaların %19,7’sinde CIN3+ saptandı. Değerlendirilen inflamatuvar belirteçler arasında yalnızca SII ile CIN3+ arasında anlamlı ilişki bulundu (p=0,004). Eğri altında kalan alan 0,647 olarak hesaplandı. 809,450 eşik değeri için duyarlılık %77,5 ve özgüllük %48,4 idi. Çok değişkenli analizde SII ≥809,450 değeri CIN3+ ile bağımsız olarak ilişkili bulundu (OR: 3,24; %95 GA: 1,45–7,23; p=0,004). Modelin açıklayıcılığı sınırlıydı (Nagelkerke R²=0,072). Tartışma: Sistemik immün-inflamasyon indeksi HPV 16 ve/veya 18 pozitif kadınlarda CIN3+ ile bağımsız olarak ilişkili bulunmuştur; ancak öngörü gücü sınırlıdır. SII, risk temelli değerlendirme modellerinde tamamlayıcı bir parametre olarak değerlendirilebilir. Anahtar Sözcükler: Servikal intraepitelyal neoplazi, insan papilloma virüsü, sistemik immün-inflamasyon indeksi, inflamasyon belirteçleri</p></trans-abstract>
                                                                                                                                    <abstract><p>ABSTRACT Objective: To evaluate whether the systemic immune-inflammation index (SII) independently predicts CIN3+ lesions in women positive for HPV 16 and/or 18. Methods: This retrospective study included 203 women aged 25 to 65 years with confirmed HPV 16 and/or 18 positivity who underwent colposcopic biopsy. Pre-biopsy complete blood count parameters were used to calculate neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and SII. Receiver operating characteristic curve analysis was performed to determine the optimal SII cut-off for predicting CIN3+. Multivariate logistic regression analysis was used to assess whether SII independently predicted CIN3+ after adjustment for age, HPV genotype, and hemoglobin level. Results: Among the evaluated markers, only SII demonstrated a statistically significant association with CIN3+ (p = 0.004). The area under the curve was 0.647. An optimal cut-off value of 809.450 yielded 77.5% sensitivity and 48.4% specificity. In multivariate analysis, SII values at or above this threshold were independently associated with CIN3+ (odds ratio 3.24, 95% confidence interval 1.45 to 7.23; p = 0.004). However, the overall explanatory power of the model was limited (Nagelkerke R² = 0.072). Conclusion: SII was independently associated with CIN3+ in women positive for HPV 16 and/or 18, although its discriminatory capacity was modest. While insufficient as a standalone triage tool, SII may provide incremental value within multifactorial risk stratification models. Prospective validation studies are warranted. Keywords: Cervical intraepithelial neoplasia, human papillomavirus, systemic inflammation markers</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Cervical intraepithelial neoplasia</kwd>
                                                    <kwd>  human papillomavirus</kwd>
                                                    <kwd>  systemic inflammation markers</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="tr">
                                                    <kwd>Servikal intraepitelyal neoplazi</kwd>
                                                    <kwd>  insan papilloma virüsü</kwd>
                                                    <kwd>  sistemik immün-inflamasyon indeksi</kwd>
                                            </kwd-group>
                                                                                                                                    <funding-group specific-use="FundRef">
                    <award-group>
                                                    <funding-source>
                                <named-content content-type="funder_name">This research received no external funding.</named-content>
                            </funding-source>
                                                                    </award-group>
                </funding-group>
                                </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">Sammarco ML, Tamburro M, Pulliero A, Izzotti A, Ripabelli G. Human papillomavirus infections, cervical cancer and MicroRNAs: an overview and implications for public health. MicroRNA. 2020;9(3):174-86.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">Malagón T, Franco EL, Tejada R, Vaccarella S. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nat Rev Clin Oncol. 2024;21(7):522-38.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">Arbyn M, Simon M, Peeters E, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083-1095.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">Munshi VN, Perkins RB, Sy MS, Kim JJ. Cost-effectiveness analysis of the 2019 ASCCP risk-based management consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Am J Obstet Gynecol. 2022;226(2):228.e1.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">Nayar R. Precision Prevention: The 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Mol Pathol. 2021;2(3):274-80.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">Dai W, Guo C, Yang Q, et al. Validation of the 2019 American Society of Colposcopy and Cervical Pathology Online Cervical Cancer Screening Program via 9 Large-Cohort Data of Chinese Women. J Low Genit Tract Dis. 2024;28(2):e34-e39.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">Karaçor T, Sak S, Barut MU, Peker N, Sak ME. Yüksek Riskli HPV Pozitif Sitolojik Sonuçların, Kolposkopik Biyopsi Sonuçları İle Karşılaştırılması. Harran Univ Med J. 2019;16(3):540-4.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">Julián RC, MRZ J. Rudolf Virchow: requiem for a visionary. Curr Inv Cln Med Res. 2021;1(1):1-5.
Chao B, Ju X, Zhang L, Xu X, Zhao Y. A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients. Front Oncol. 2020;10:766.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">Zhu M, Feng M, He F, Han B, Ma K, Zeng X, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical cancer. Clin Chim Acta. 2018;483:296-302.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">Inturrisi F, Bogaards JA, Heideman DA, Meijer CJ, Berkhof J. Risk of cervical intraepithelial neoplasia grade 3 or worse in HPV-positive women with normal cytology and five-year type concordance: a randomized comparison. Cancer Epidemiol Biomarkers Prev. 2021;30(3):485-91.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">Cim N, Ayguler E, Gunal N, Cim B, Atalmis HA, Cetin A. Systemic Inflammatory Response Index in Cervical Pathologies (Human Papillomavirus and Cervical Neoplasia) and its Prognostic Value in Disease Prediction. Niger J Clin Pract. 2025;28(5):615-23.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">Qin L, Zhang L. The predictive value of serum inflammatory markers for the severity of cervical lesions. BMC Cancer. 2024;24(1):780.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">Sadri NJ, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int J Cancer. 2020;146(2):305-20.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">Ilhan ZE, Łaniewski P, Thomas N, et al. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019;44:675-90.
Tas M, Yavuz A, Ak M, Ozcelik B. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Discriminating Precancerous Pathologies from Cervical Cancer. J Oncol. 2019;2019:2476082.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2020;99(1):e18571.
Holub K, Biete A. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol. 2019;21(7):836-44.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">Ozdemir CY, Cicekli N, Ahat B, et al. Effect of hemoglobin, albumin, lymphocyte, and platelet score on prognosis in intermediate-risk endometrial cancer according to molecular-based classification. J Obstet Gynaecol Res. 2024;50(11):2107-2112.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">Staniewska E, Grudzien K, Stankiewicz M, et al. The prognostic value of the systemic immune-inflammation index (SII) and red cell distribution width (RDW) in patients with cervical cancer treated using radiotherapy. Cancers (Basel). 2024;16(8):1542.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
